scholarly journals Patient-Support Program in Diabetes Care During the Covid-19 Pandemic: An Italian Multicentric Experience

2022 ◽  
Vol Volume 16 ◽  
pp. 113-122
Author(s):  
Annalisa Natalicchio ◽  
Camilla Sculco ◽  
Gianni Belletti ◽  
Martina Fontanelli ◽  
Carlotta Galeone ◽  
...  
Keyword(s):  
Diabetes Care ◽  
Support Program ◽  
Patient Support ◽  
Patient Support Program

Impact of a Structured Patient-Support Program on Adherence and Persistence with Basal Insulin Therapy at 12 Months

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1267-P
Author(s):  
FANG L. ZHOU ◽  
JASON YEAW ◽  
SWAPNA KARKARE ◽  
MITCH DEKOVEN ◽  
TIMOTHY S. REID
Keyword(s):  
Insulin Therapy ◽  
Basal Insulin ◽  
Support Program ◽  
Patient Support ◽  
Patient Support Program

scholarly journals Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Aline Bourdin ◽  
Marie Paule Schneider ◽  
Isabella Locatelli ◽  
Myriam Schluep ◽  
Olivier Bugnon ◽  
...  
Keyword(s):  
Patient Safety ◽  
Medication Adherence ◽  
Real World ◽  
Safety Data ◽  
Support Program ◽  
Patient Support ◽  
Patient Support Program ◽  
Dose Monitoring ◽  
Real World Evidence ◽  
Patient Reported

AbstractThe Fingolimod Patient Support Program (F-PSP) is an interprofessional specialty pharmacy service designed to ensure responsible use of fingolimod by promoting patient safety and medication adherence. This study aims to evaluate the safety and medication adherence of patients who joined the F-PSP between 2013 and 2016. Sociodemographic and medical characteristics, patient safety data (patient-reported symptoms, discontinuations due to adverse events (AEs), repeated first-dose monitoring), and medication adherence (implementation, persistence, reasons for discontinuation, influence of covariates, barriers and facilitators) were described. Sixty-seven patients joined the F-PSP. Patients reported a high frequency of symptoms. Due to AEs, 7 patients discontinued fingolimod, 3 took therapeutic breaks, and 1 reduced the regimen temporarily. Three patients repeated the first-dose monitoring. Patients had a high medication adherence over the 18-month analysis period: implementation decreased from 98.8 to 93.7%, and fingolimod persistence was 83.2% at 18 months. The patients’ level of education, professional situation, and living with child(ren) influenced implementation. Patients reported more facilitators of medication adherence than barriers. The F-PSP seems valuable for supporting individual patients (ensuring responsible use of fingolimod and inviting patients for shared-decision making) and public health (indirectly gathering real-world evidence).

Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis — A prospective study

2010 ◽  
Vol 4 (2) ◽  
pp. 171-175 ◽  
Author(s):  
Alan C. Moss ◽  
Nabeel Chaudhary ◽  
Melissa Tukey ◽  
Jahvari Junior ◽  
Didia Cury ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Prospective Study ◽  
Support Program ◽  
Patient Support ◽  
Patient Support Program ◽  
A Prospective Study

scholarly journals Optimizing insulin initiation in primary care: the Diabetes CoStars patient support program

2016 ◽  
pp. 3
Author(s):  
Hazel Palmer ◽  
Olga Lutzko ◽  
Helen Schifferle ◽  
Marita Ariola ◽  
Khen Meng-Kon ◽  
...  
Keyword(s):  
Primary Care ◽  
Support Program ◽  
Patient Support ◽  
Insulin Initiation ◽  
Patient Support Program

Biosimilar trastuzumab active post marketing surveillance real world 2020 data update: Results from a patient support program for patients under treatment with the first biosimilar trastuzumab approved in Brazil.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e14504-e14504
Author(s):  
Allisson Monteiro da Silva ◽  
Thais Tiemi Wepeck Oliveira Watanabe ◽  
Eimy Honda ◽  
Juliana Yamaguchi
Keyword(s):  
Breast Cancer ◽  
Adverse Events ◽  
Support Program ◽  
Surveillance Program ◽  
Postmarketing Surveillance ◽  
Patient Support ◽  
Patient Support Program ◽  
Her2 Breast Cancer ◽  
Phone Calls ◽  
Post Marketing Surveillance

e14504 Background: In 2017, biosimilar trastuzumab (Zedora) became the first biosimilar trastuzumab approved in Brazil. In May 2018 an active postmarketing surveillance program was instituted. Data from this program was presented in ASCO in 2019 and 2020. Now, with an extended follow up (May 2018 to December 2020) and more patients included, we present updated data from the surveillance program. Methods: This is a prospective observational study to evaluate data from the patient support program. Patients who received prescription for biosimilar trastuzumab were invited to participate. After agreement of informed consent, they were followed by periodical phone calls after each infusion and up to 3 months after the end of treatment. Treatment related data and adverse events (AEs) were collected. Results: A total of 74 reports containing 656 adverse events (AEs) were received from the active postmarketing surveillance program between May 2018 and December 2020. Of the 74 reports, 73 are female patients with HER2+ breast cancer (BC) and 1 is a male patient with gastric adenocarcinoma. The patients mean age was 52 years (31 to 79 years). Regarding to AEs severity and expectedness, 588 (89.63%) were non-serious AE (413 expected / 175 unexpected) and 68 (10.37%) were serious AE (51 expected / 17 unexpected). Considering all serious unexpected AEs (17), 13 were assessed as not related to trastuzumab therapy and 4 were assessed as related to therapy. For the 175 non-serious unexpected AEs, 56 were assessed as not related to therapy and 119 were assessed as related to therapy. The three most frequently reported AEs according to SOC (System Organ Classification) were general disorders and administration site conditions 111 (16.92%), gastrointestinal disorders 98 (14.93%) and nervous system disorders 88 (13.41%). The five most commonly reported adverse events (MedDRA PT - Preferred term) were diarrhea 27 (4.11%), fatigue 24 (3.66%), nausea 22 (3.35%), weight decreased 18 (2.74%) and infusion related reaction 17 (2.59%). Further monitoring is continued. Conclusions: Nature of AEs noted in patients with breast cancer and gastric cancer treated with biosimilar trastuzumab (Zedora) were consistent with the known safety profile of Trastuzumab. The risk benefit remains consistent with the reference safety information and no new safety signals were detected.[Table: see text]

Sign in / Sign up

Export Citation Format

Share Document